NF-kappa B
NF-κB is the transcription factor that coordinates skin inflammation – and the single molecular node through which chronic inflammatory signals simultaneously damage the barrier and degrade the dermis. At rest, its p50/p65 heterodimer is held inactive by IκBα. UV exposure, allergen penetration, glycation, oxidative stress, and the TNF-α autocrine loop all trigger IκBα degradation, freeing NF-κB to drive two parallel destructive outputs: suppression of filaggrin and ceramide synthesis via IL-4 and IL-13, and upregulation of MMP-1, MMP-3, and MMP-9 in keratinocytes and fibroblasts. In ageing skin, senescent cells maintain constitutive NF-κB activation through SASP, making the inflammatory environment self-sustaining without external triggers. Polynucleotides, CAP, and omega-3 fatty acids each suppress NF-κB through distinct mechanisms – A2A receptor activation, RONS-mediated IKK inhibition, and PPARα-dependent p65 translocation blockade respectively – addressing both damage tracks from the same upstream intervention.
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is the transcription factor that sits at the convergence of almost every inflammatory pathway relevant to skin ageing and barrier dysfunction. It is not a single molecule but a family of Rel proteins, with the p50/p65 heterodimer as the canonical, skin-relevant form. What makes it so clinically significant – and why it earns its own entity despite appearing as a supporting character in so many others – is that its activation produces two distinct categories of damage simultaneously: it suppresses the barrier proteins that maintain the stratum corneum, and it upregulates the enzymes that degrade the collagen and elastin that give skin its structure. A single inflammatory event can drive both. Understanding NF-κB as the shared mechanism behind these two tracks changes how treatment sequencing makes sense.
The IκB Switch
At rest, NF-κB’s p50/p65 heterodimer is held inactive in the cytoplasm, bound to its inhibitor protein IκBα (inhibitor of kappa B). When an activation signal arrives, the IKK kinase complex (IκB kinase) phosphorylates IκBα, marking it for ubiquitination and proteasomal degradation. With IκBα gone, free p50/p65 translocates into the nucleus, binds κB response elements in target gene promoters, and initiates transcription. The whole cycle from signal to transcription can complete within an hour. [2]
The speed and reversibility of this switch is part of what makes NF-κB both essential and dangerous. Under normal conditions it enables the rapid inflammatory responses that initiate wound healing and fight infection. The problem emerges when activation becomes chronic – when the signals never fully resolve and the switch is never fully returned to its resting state. That low-grade, persistent NF-κB activity is the molecular environment of inflammageing.
What Activates NF-κB in Skin
The triggers are numerous, but the clinically relevant categories follow recognisable patterns:
UV radiation activates NF-κB in keratinocytes within hours of exposure via nitric oxide synthase and IκB reduction, producing the inflammatory cytokine cascade – VEGF, TNF-α, IL-1β, IL-6 – that underlies sunburn and, with cumulative exposure, photoageing. [1]
Barrier disruption and allergen penetration – when the stratum corneum is compromised, whether by hard water, alkaline cleansers, or filaggrin deficiency, allergens and irritants reach Langerhans cells and keratinocytes that would otherwise never encounter them. This triggers innate NF-κB activation, which produces the Th2-polarising cytokines that suppress filaggrin further. The barrier disruption creates the very inflammatory signal that prevents the barrier from repairing itself.
Advanced glycation end products (AGEs) bind the RAGE receptor (receptor for AGEs) on keratinocytes and fibroblasts, activating NF-κB independently of UV or allergen exposure. This is the mechanism connecting high dietary sugar load, Type 2 diabetes, and glycation-driven skin deterioration directly to the same inflammatory pathway.
Reactive oxygen species and mitochondrial dysfunction activate the IKK complex directly, linking oxidative stress from ageing mitochondria, pollution exposure, and metabolic dysregulation to NF-κB-driven inflammation. This is one of the reasons oxidative stress and inflammation in ageing skin are not two separate problems – they share a common signal amplification node.
The TNF-α autocrine loop deserves specific mention. NF-κB produces TNF-α as one of its transcriptional outputs, and TNF-α is itself a potent NF-κB activator. Once this cycle initiates, it sustains itself without ongoing external stimulus – which is why chronic skin inflammation so rarely resolves spontaneously once established. [6]
| Trigger | Activation mechanism | Primary skin consequence |
|---|---|---|
| UV radiation | NOS-mediated IκBα reduction within hours of exposure | VEGF, TNF-α, IL-1β, IL-6 cascade; photoageing with cumulative exposure |
| Barrier disruption / allergen penetration | Allergens reach Langerhans cells and keratinocytes through compromised SC | Th2 polarisation → IL-4/IL-13 → further filaggrin suppression |
| AGEs via RAGE receptor | RAGE binding activates IKK complex on keratinocytes and fibroblasts | Links dietary glycaemic load and Type 2 diabetes directly to inflammatory pathway |
| ROS / mitochondrial dysfunction | Direct IKK complex activation | Oxidative stress and inflammation as a shared rather than separate signal |
| TNF-α autocrine loop | NF-κB-produced TNF-α re-activates NF-κB | Self-sustaining inflammation without ongoing external trigger |
Two Tracks, One Activation Event
This is where NF-κB becomes unusually consequential. Most inflammatory mediators cause damage through one primary mechanism. NF-κB causes it through two simultaneously.
Track 1 – Barrier protein suppression. NF-κB drives production of IL-4 and IL-13 through Th2 immune polarisation downstream of its innate inflammatory signalling. These cytokines directly suppress FLG gene expression in keratinocytes – IL-4 and IL-13 exposure reduces filaggrin production to approximately 25% of baseline in primary keratinocyte research, regardless of FLG genotype. Loss of filaggrin removes NMF-derived acidification pathways (PCA and urocanic acid), raises stratum corneum pH, impairs ceramide-processing enzyme activity, and initiates the barrier-inflammation feedback loop described in the Filaggrin entity. Every step of the cascade traces back to the same NF-κB activation that began with UV, hard water, or stress.
Track 2 – Structural matrix degradation. NF-κB directly upregulates MMP-1 (interstitial collagenase), MMP-3 (stromelysin), and MMP-9 in both keratinocytes and dermal fibroblasts. MMP-1 cleaves native fibrillar collagen I and III at a single site within the triple helix; MMP-3 and MMP-9 degrade the resulting fragments and activate other MMPs; MMP-9 additionally degrades type IV collagen in the basement membrane. This is the primary mechanism connecting chronic inflammation to visible structural skin ageing – the reason that photoaged, chronically inflamed, metabolically stressed, and senescent skin all converge on the same pattern of collagen loss and dermal thinning regardless of which trigger initiated the process. [5]
Both tracks operate in parallel from the same activation event. A UV-exposed client with atopic tendency and a high dietary glycaemic load is not running three separate inflammatory processes – they are running three inputs into one transcription factor producing both outputs at once.
Clinical Pearl The two-track model has a direct implication for treatment sequencing. Treatments that suppress NF-κB (polynucleotides, CAP, omega-3) address both the barrier suppression and the MMP-driven structural degradation tracks simultaneously. They belong before synthesis-stimulating treatments in presentations where inflammation is ongoing – not because they have stronger synthesis effects, but because they remove the active suppression that would otherwise limit the response to whatever stimulates synthesis next.
The Senescence Loop
NF-κB and cellular senescence share a bidirectional relationship that makes each worse over time. Persistent NF-κB activation drives keratinocytes and fibroblasts toward growth arrest and senescence. Senescent cells then constitutively activate NF-κB to maintain their SASP (senescence-associated secretory phenotype) – producing IL-6, IL-8, and TNF-α that activate NF-κB in surrounding non-senescent cells, propagating the senescent microenvironment laterally through tissue. [2]
This loop is what makes inflammageing self-sustaining. Once a sufficient population of senescent cells has accumulated, NF-κB maintains low-grade chronic inflammation without needing exogenous triggers – which is why clients in their 50s and 60s can present with progressive barrier deterioration and collagen loss despite no change in external exposures, skincare, or lifestyle. The driver has become internal.
Clinical Application
The treatments that suppress NF-κB do so through four distinct mechanisms – understanding which route each takes explains both what they share and why combining them often produces outcomes neither achieves alone.
| Treatment | NF-κB suppression mechanism | Outputs reduced | Clinical positioning |
|---|---|---|---|
| Polynucleotides (PDRN/PN) | A2A receptor → G-protein signalling → IKK suppression | TNF-α, IL-6, IL-12, MMP-1, MMP-3, MMP-9 | Barrier + collagen protection simultaneously; confirmed via A2A antagonist reversal |
| Cold atmospheric plasma (CAP) | Sub-damaging RONS → oxidative IKK inactivation | IL-4, IL-13, IL-31 | Most direct for acquired filaggrin suppression; dose-dependent – therapeutic window matters |
| Omega-3 (EPA/DHA) | Oxidised EPA → PPARα-dependent p65 translocation blockade | MMP upregulation, Th2 cytokine environment | Systemic upstream modulation; PPARα-null cells show no effect, confirming receptor specificity |
| GHK-Cu | NF-κB and downstream MMP suppression | MMP-1, MMP-3 | Collagen-protective; mechanism detail in Copper Peptide entity |
| Beta-hydroxybutyrate | Indirect via NLRP3 inflammasome inhibition | IL-1β, IL-18 | Metabolic route; mechanism detail in BHB entity |
Polynucleotides ( PDRN/PN) activate adenosine A2A receptors on immune cells and keratinocytes, initiating G-protein signalling that suppresses IKK activation and reduces NF-κB nuclear translocation. The downstream result is decreased production of TNF-α, IL-6, and IL-12 alongside reduced MMP-1, MMP-3, and MMP-9. This mechanism has been confirmed specifically in a psoriasis model using PDRN, where co-administration of the A2A receptor antagonist istradefylline reversed the anti-inflammatory effect – establishing the A2A route as the operative mechanism rather than a non-specific anti-inflammatory effect. [3] The collagen-protective consequence of polynucleotide NF-κB suppression is described in detail in the Collagen entity; the barrier-protective consequence in the Filaggrin entity. Both effects trace to the same NF-κB suppression mechanism.
Cold atmospheric plasma (CAP) generates reactive oxygen and nitrogen species at sub-damaging concentrations at the skin surface. Paradoxically, whilst high-level ROS activates NF-κB via IKK, the controlled RONS levels generated by CAP suppress NF-κB through oxidative inactivation of IKK at a dose below the threshold that would activate the pathway. The result is reduced IL-4, IL-13, and IL-31 in atopic skin models, with helium and argon plasma producing more pronounced cytokine suppression than air plasma. This is a dose-dependent mechanism – it is the controlled, therapeutic delivery that distinguishes CAP’s NF-κB suppression from the NF-κB activation that high oxidative stress produces.
Omega-3 fatty acids via PPARα represent the dietary NF-κB suppression route. Oxidised EPA inhibits nuclear translocation of the p50/p65 heterodimer through a PPARα-dependent mechanism – the effect is absent in PPARα-null cells, confirming this is not a direct antioxidant effect but a specific receptor-mediated pathway. [4] At the therapeutic dosing range of 2–3 g EPA/DHA daily, this PPARα/NF-κB antagonism provides meaningful systemic modulation of the inflammatory environment – addressing both tracks (barrier suppression and MMP upregulation) from an oral, upstream position.
GHK-Cu (copper peptide) suppresses NF-κB and its downstream MMP expression, contributing to its collagen-protective activity. This mechanism is described in the Copper Peptide entity; it is included here to complete the NF-κB inhibitor map.
Beta-hydroxybutyrate (BHB) suppresses NF-κB indirectly via NLRP3 inflammasome inhibition, representing the metabolic route – described in the Beta-Hydroxybutyrate entity.
References
Abeyama K, Eng W, Jester JV, et al. (2000). A role for NF-kappaB-dependent gene transactivation in sunburn. J Clin Invest, 105(12), 1751-9 . doi.org/10.1172/jci9745
Haga M, Okada M (2022). Systems approaches to investigate the role of NF-κB signaling in aging. Biochem J, 479(2), 161-183 . doi.org/10.1042/bcj20210547
Irrera N, Bitto A, Vaccaro M, et al. (2020). PDRN, a Bioactive Natural Compound, Ameliorates Imiquimod-Induced Psoriasis through NF-κB Pathway Inhibition and Wnt/β-Catenin Signaling Modulation. Int J Mol Sci, 21(4) . doi.org/10.3390/ijms21041215
Mishra A, Chaudhary A, Sethi S (2004). Oxidized omega-3 fatty acids inhibit NF-kappaB activation via a PPARalpha-dependent pathway. Arterioscler Thromb Vasc Biol, 24(9), 1621-7 . doi.org/10.1161/01.atv.0000137191.02577.86
Pittayapruek P, Meephansan J, Prapapan O, et al. (2016). Role of Matrix Metalloproteinases in Photoaging and Photocarcinogenesis. Int J Mol Sci, 17(6) . doi.org/10.3390/ijms17060868
Ren Q, Qu L, Yuan Y, et al. (2024). Natural Modulators of Key Signaling Pathways in Skin Inflammageing. Clin Cosmet Investig Dermatol, 17, 2967-2988 . doi.org/10.2147/ccid.s502252
Also Known As
- kappa B enhancer binding protein
- NF-kB
- NF-κB
- nuclear factor kappa B
- nuclear factor kappa-light-chain-enhancer of activated B cells
Learn More
This topic is discussed in 2 articles:
-
A key transcription factor in inflammatory signalling. NF-κB drives the production of pro-inflammatory cytokines including IL-4 and IL-13 in atopic dermatitis and barrier-compromised skin. Polynucleotides (PDRN/PN) suppress the NF-κB pathway by activating adenosine A2A receptors, thereby reducing the cytokine production that perpetuates barrier dysfunction.
-
The master transcription factor coordinating skin inflammation. NF-κB activation simultaneously suppresses barrier proteins and upregulates collagen-degrading MMPs.
-
The master transcription factor coordinating skin inflammation. NF-κB activation simultaneously suppresses barrier proteins and upregulates collagen-degrading MMPs.